S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:EYPT

EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price & News

$9.51
+0.02 (+0.21%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$9.43
$9.74
50-Day Range
$8.69
$13.08
52-Week Range
$7.30
$21.50
Volume
69,413 shs
Average Volume
115,622 shs
Market Capitalization
$323.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EyePoint Pharmaceuticals logo

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYPT
Employees
122
Year Founded
1987

Sales & Book Value

Annual Sales
$35.31 million
Book Value
$4.90 per share

Profitability

Net Income
$-58.42 million
Net Margins
-174.09%
Pretax Margin
-174.09%

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,943,000
Market Cap
$323.82 million
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/22/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

267th out of 1,416 stocks

Analytical Instruments Industry

10th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -













EyePoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

Is EyePoint Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EyePoint Pharmaceuticals stock.
View analyst ratings for EyePoint Pharmaceuticals
or view top-rated stocks.

When is EyePoint Pharmaceuticals' next earnings date?

EyePoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for EyePoint Pharmaceuticals
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.02. The company earned $9.29 million during the quarter, compared to analysts' expectations of $10.35 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 47.60% and a negative net margin of 174.09%. During the same period last year, the business earned ($0.50) EPS.
View EyePoint Pharmaceuticals' earnings history
.

When did EyePoint Pharmaceuticals' stock split? How did EyePoint Pharmaceuticals' stock split work?

Shares of EyePoint Pharmaceuticals reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of EyePoint Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for EYPT?

3 equities research analysts have issued twelve-month price objectives for EyePoint Pharmaceuticals' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate EyePoint Pharmaceuticals' stock price to reach $29.50 in the next year. This suggests a possible upside of 210.2% from the stock's current price.
View analysts' price targets for EyePoint Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are EyePoint Pharmaceuticals' key executives?
EyePoint Pharmaceuticals' management team includes the following people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 65, Pay $1.05M)
  • Mr. George O. Elston, Chief Financial Officer (Age 57, Pay $692.6k)
  • Dr. Jay S. Duker M.D., Chief Operating Officer (Age 63, Pay $28.23k)
  • Dr. Dario A. Paggiarino, Sr. VP & Chief Medical Officer (Age 65, Pay $694.19k)
  • Mr. David Scott Jones, Sr. VP & Chief Commercial Officer (Age 55, Pay $604.04k)
  • Mr. Said Saim, Chief Technology Officer (Age 64)
  • Mr. Ron I. Honig Esq., Chief Legal Officer & Company Sec.
  • Mr. Michael Pine, Chief Corp. Devel. & Strategy Officer
  • Ms. Jennifer Leonard, Chief People Officer & Sr. VP of IT
  • Ms. Isabelle Lefebvre, Chief Regulatory Officer
What other stocks do shareholders of EyePoint Pharmaceuticals own?
What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Suvretta Capital Management LLC (8.55%), BlackRock Inc. (4.48%), Vanguard Group Inc. (3.62%), Goldman Sachs Group Inc. (2.56%), Verition Fund Management LLC (1.34%) and State Street Corp (1.10%).
View institutional ownership trends for EyePoint Pharmaceuticals
.

Which institutional investors are selling EyePoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., and Simplex Trading LLC.
View insider buying and selling activity for EyePoint Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying EyePoint Pharmaceuticals stock?

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Goldman Sachs Group Inc., Verition Fund Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, Essex Investment Management Co. LLC, Vanguard Group Inc., and Northern Trust Corp.
View insider buying and selling activity for EyePoint Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $9.51.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals has a market capitalization of $323.82 million and generates $35.31 million in revenue each year. The company earns $-58.42 million in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals employs 122 workers across the globe.

When was EyePoint Pharmaceuticals founded?

EyePoint Pharmaceuticals was founded in 1987.

What is EyePoint Pharmaceuticals' official website?

The official website for EyePoint Pharmaceuticals is eyepointpharma.com.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at (617) 926-5000, via email at [email protected], or via fax at 617-926-5050.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.